Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Weekly News Recap #Phispers
Drugs in Development
Details:
BGB-A1217 (ociperlimab) is an anti-TIGIT antibody candidate, which is being evaluated for the treatment of lung cancer.
Lead Product(s): Ociperlimab,Tislelizumab
Therapeutic Area: Oncology Brand Name: BGB-A1217
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2025
Lead Product(s) : Ociperlimab,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Details : BGB-A1217 (ociperlimab) is an anti-TIGIT antibody candidate, which is being evaluated for the treatment of lung cancer.
Product Name : BGB-A1217
Product Type : Antibody
Upfront Cash : Inapplicable
April 03, 2025
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized IgG4 PD-1 mAb, being evaluated for extensive-stage small cell lung cancer in combination with etoposide and platinum chemotherapy.
Lead Product(s): Tislelizumab,Cisplatin,Etoposide
Therapeutic Area: Oncology Brand Name: Tevimbra
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025
Lead Product(s) : Tislelizumab,Cisplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for ESSCLC
Details : Tevimbra (tislelizumab) is a uniquely designed humanized IgG4 PD-1 mAb, being evaluated for extensive-stage small cell lung cancer in combination with etoposide and platinum chemotherapy.
Product Name : Tevimbra
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2025
Details:
Decoy20 is an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
Lead Product(s): Decoy20,Tislelizumab
Therapeutic Area: Oncology Brand Name: Decoy20
Study Phase: Phase I/ Phase IIProduct Type: Microorganism
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Decoy20,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indaptus’ Decoy20 Weekly Dosing Shows Broad Immune System Activation
Details : Decoy20 is an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
Product Name : Decoy20
Product Type : Microorganism
Upfront Cash : Inapplicable
March 20, 2025
Details:
Decoy20, an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
Lead Product(s): Decoy20,Tislelizumab
Therapeutic Area: Oncology Brand Name: Decoy20
Study Phase: Phase I/ Phase IIProduct Type: Microorganism
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Decoy20,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indaptus Starts Phase 1 Decoy20 Combo Trial with Tislelizumab
Details : Decoy20, an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
Product Name : Decoy20
Product Type : Microorganism
Upfront Cash : Inapplicable
March 18, 2025
Details:
EVM16 is an innovative personalized therapeutic mRNA cancer vaccine, which is currently being evaluated in combination with tislelizumab for the treatment of advanced or Recurrent solid tumors.
Lead Product(s): EVM16,Tislelizumab
Therapeutic Area: Oncology Brand Name: EVM16
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025
Lead Product(s) : EVM16,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Everest Doses First Patient with EVM16, A Personalized mRNA Cancer Vaccine
Details : EVM16 is an innovative personalized therapeutic mRNA cancer vaccine, which is currently being evaluated in combination with tislelizumab for the treatment of advanced or Recurrent solid tumors.
Product Name : EVM16
Product Type : Vaccine
Upfront Cash : Inapplicable
March 06, 2025
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized IgG4 PD-1 mAb, being evaluated for the treatment of first-line treatment of advanced esophageal squamous cell carcinoma.
Lead Product(s): Tislelizumab,Cisplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: Tevimbra
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2025
Lead Product(s) : Tislelizumab,Cisplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TEVIMBRA Approved in U.S. for First-Line Esophageal Cancer Treatment with Chemo
Details : Tevimbra (tislelizumab) is a uniquely designed humanized IgG4 PD-1 mAb, being evaluated for the treatment of first-line treatment of advanced esophageal squamous cell carcinoma.
Product Name : Tevimbra
Product Type : Antibody
Upfront Cash : Inapplicable
March 04, 2025
Details:
Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Lead Product(s): Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area: Oncology Brand Name: Bria-OTS
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Announces Resolution of Lung Metastasis in First Patient Treated with Bria-OTS™
Details : Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Product Name : Bria-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 03, 2025
Details:
Under the agreement, combining BeiGene's Tevimbra (tislelizumab), a PD-1 checkpoint inhibitor, and ImmunityBio's Anktiva, to conduct a confirmatory randomized Phase 3 clinical trial for S-IV NSCLC.
Lead Product(s): Tislelizumab,Docetaxel,Nogapendekin Alpha Inbakicept
Therapeutic Area: Oncology Brand Name: Tevimbra
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2025
Lead Product(s) : Tislelizumab,Docetaxel,Nogapendekin Alpha Inbakicept
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BeiGene
Deal Size : Undisclosed
Deal Type : Collaboration
ImmunityBio, BeiGene Collaborate on Phase 3 ANKTIVA, PD-1 Trial in NSCLC
Details : Under the agreement, combining BeiGene's Tevimbra (tislelizumab), a PD-1 checkpoint inhibitor, and ImmunityBio's Anktiva, to conduct a confirmatory randomized Phase 3 clinical trial for S-IV NSCLC.
Product Name : Tevimbra
Product Type : Antibody
Upfront Cash : Undisclosed
January 29, 2025
Details:
Under the terms of the agreement, MAIA will sponsor and fund the planned clinical trials of THIO-102 and BeiGene will provide Tislelizumab for hepatocellular carcinoma, SCLC, and CRC.
Lead Product(s): THIO-102,Tislelizumab
Therapeutic Area: Oncology Brand Name: THIO-102
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 07, 2025
Lead Product(s) : THIO-102,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : BeiGene
Deal Size : Undisclosed
Deal Type : Agreement
MAIA, BeiGene Collaborate for Phase 2 Cancer Trials Clinical Supply
Details : Under the terms of the agreement, MAIA will sponsor and fund the planned clinical trials of THIO-102 and BeiGene will provide Tislelizumab for hepatocellular carcinoma, SCLC, and CRC.
Product Name : THIO-102
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2025
Details:
BeiGene has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an ADC, BG-C9074 (DB-1312) from DualityBio.
Lead Product(s): DB-1312,Tislelizumab
Therapeutic Area: Oncology Brand Name: DB-1312
Study Phase: Phase IProduct Type: Other Large Molecule
Sponsor: BeiGene
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2025
Lead Product(s) : DB-1312,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : BeiGene
Deal Size : $1,300.0 million
Deal Type : Licensing Agreement
Nona Biosciences Updates on DualityBio's ADC Collaboration with BeiGene
Details : BeiGene has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an ADC, BG-C9074 (DB-1312) from DualityBio.
Product Name : DB-1312
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 03, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
